Article Text

other Versions

PDF

Comment on ‘End of the road for Essure®?’
  1. Sayantana Das,
  2. Wai Cheong Yoong,
  3. Abha Govind
  1. Department of Obstetrics and Gynaecology, North Middlesex University Hospital NHS Trust, London, UK
  1. Correspondence to Dr Sayantana Das, Department of Obstetrics and Gynaecology, North Middlesex University Hospital NHS Trust, London N18 1QX, UK; sayantana_dr{at}yahoo.co.in

Statistics from Altmetric.com

We read David Horwell’s letter ‘End of the road for Essure®?’ published in the July 2017 issue of this journal with interest.1While Bayer’s decision is understandable, it is also disappointing. Essure’s withdrawal from the market leaves laparoscopic clip sterilisation and open tubal ligation (at caesarean delivery), as the only methods for female sterilisation available in UK. Clinicians will have to wait for future hysteroscopic alternatives to emerge to broaden the choice for women once more. This will be difficult in the light of the lawsuits attracted by Essure and the withdrawal of Adiana in 2012 due to its high failure rate and the manufacturer’s inability to keep up with legal costs over patent infringement litigation.2

Having offered the Essure device to our patients we had …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.